U.S. development phase success rates for drugs with and without biomarkers 2011-2020

This statistic shows the probability of success for new drugs with and without biomarkers in the U.S. through the various stages of development, in the period from January 1, 2011, to November 30, 2020. It was found that while the probability that a new drug without biomarkers makes it from phase I to approval was only 7.6 percent, those with selection biomarkers had a probability of success of 15.9 percent.

本统计数据显示了2011年1月1日至2020年11月30日期间，美国新药在具有与不具有生物标志物的情况下，从研发初期至获得批准各阶段成功的概率。研究发现，无生物标志物的新药从I期至批准的成功概率仅为7.6%，而具有选择生物标志物的新药成功概率则为15.9%。